Table 1.
Demographic and clinical characteristics of the sample (n=189).
| Variables | Immediate access group (n=94) | Delayed access control group (n=95) | 2-tailed t test (df) | Chi-square (df) | P value | |||||||||
| Age (years), mean (SD) | 35.82 (10.76) | 37.06 (12.27) | −0.09 (163) | N/Aa | .92 | |||||||||
| Sex, n (%) | N/A | 0.05 (2) | .82 | |||||||||||
|
|
Female | 78 (83) | 80 (84) |
|
|
|
||||||||
|
|
Male | 16 (17) | 15 (16) |
|
|
|
||||||||
| Recruitment, n (%) | N/A | 15.8 (2) | .045 | |||||||||||
|
|
Search engines | 52 (58) | 51 (60) |
|
|
|
||||||||
|
|
Referral | 18 (20) | 9 (11) |
|
|
|
||||||||
|
|
9 (10) | 2 (2) |
|
|
|
|||||||||
|
|
4 (5) | 11 (13) |
|
|
|
|||||||||
|
|
YouTube | 2 (2) | 4 (5) |
|
|
|
||||||||
|
|
2 (2) | 1 (1) |
|
|
|
|||||||||
|
|
Television news | 2 (2) | 3 (4) |
|
|
|
||||||||
|
|
0 (0) | 2 (2) |
|
|
|
|||||||||
|
|
Direct access to the website | 0 (0) | 2 (2) |
|
|
|
||||||||
| Completer, n (%) | 44 (47) | 29 (31) | N/A | 9.97 (2) | .002 | |||||||||
| Dropped out, n (%) | 50 (53) | 66 (69) | N/A | 9.97 (2) | .002 | |||||||||
| PHQ-9b preintervention scorec, mean (SD) | 19.57 (4.81) | 20.12 (4.41) | −0.74 (163) | N/A | .46 | |||||||||
| Severity PHQ-9, n (%) | N/A | 3.38 (2) | N/A | |||||||||||
|
|
Moderately severe and severe | 80 (85) | 82 (86) |
|
|
|
||||||||
|
|
Moderate | 14 (15) | 13 (14) |
|
|
|
||||||||
| CORE-OMd preintervention score, mean (SD) | 82.90 (16.34) | 86.84 (17.22) | −1.74 (163) | N/A | .08 | |||||||||
| GSESe, mean (SD) | ||||||||||||||
|
|
Preintervention score | 23.06 (6.32) | 12.08 (6.94) | 1.60 (163) | N/A | .11 | ||||||||
| Diagnosis, n (%) | N/A | 0.12 (2) | .72 | |||||||||||
|
|
Never diagnosed | 41 (44) | 39 (41) |
|
|
|
||||||||
|
|
Diagnosed | 53 (56) | 56 (59) |
|
|
|
||||||||
| Concurrent treatments, n (%) | N/A | 0.46 (2) | .50 | |||||||||||
|
|
Not in treatment | 59 (63) | 54 (57) |
|
|
|
||||||||
|
|
Pharmacology | 20 (21) | 26 (27) |
|
|
|
||||||||
|
|
Psychotherapy | 8 (9) | 7 (7) |
|
|
|
||||||||
|
|
Both treatments | 7 (8) | 8 (8) |
|
|
|
||||||||
| Comorbidities, n (%) | N/A | 0.29 (2) | .59 | |||||||||||
|
|
No comorbidities | 33 (35) | 37 (39) |
|
|
|
||||||||
|
|
Comorbidities | 61 (65) | 58 (61) |
|
|
|
||||||||
| Pandemics, n (%) | N/A | 0.00 (2) | .95 | |||||||||||
|
|
Before | 45 (48) | 45 (47) |
|
|
|
||||||||
|
|
After | 49 (52) | 50 (53) |
|
|
|
||||||||
aN/A: not applicable.
bPHQ-9: Patient Health Questionnaire–9.
cThe PHQ-9 has a total score of 10 to 14 for moderate depressive symptoms, 15 to 19 for moderately severe depressive symptoms, and 20 to 27 for severe depressive symptoms [36,37].
dCORE-OM: Clinical Outcome in Routine Evaluation–Outcome Measurement.
eGSES: general self-efficacy scale.